Clinical Trial Update: Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lanreotide 120 mg as palliative treatment for symptoms of malignant bowel obstruction in inoperable patients; the study has completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Bowel Obstruction

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Malignant Intestinal Obstruction | Phase 2 | Status: COMPLETED